P27 Deregulation in Breast Cancer: Prognostic Significance and Implications for Therapy

Overview

Journal J Mammary Gland Biol Neoplasia

Date 2004 Apr 15

PMID 15082919

Citations 42

Authors

A Alkarain

R Jordan

J Slingerland

Affiliations

Soon will be listed here.

Abstract

p27 is a key regulator of G1-to-S phase progression. It prevents premature activation of cyclin E-cdk2 in G1 and promotes the assembly and activation of D-type cyclin-cdks. While the p27 gene is rarely mutated in human cancers, the action of p27 is impaired in breast and other human cancers through accelerated p27 proteolysis, sequestration by cyclin D-cdks, and by p27 mislocalization in tumor cell cytoplasm. Reduced p27 protein is strongly associated with high histopathologic tumor grade, reflecting a lack of tumor differentiation. Loss of p27 is also an indicator of poor patient outcome in a majority of breast cancer studies, including node negative disease. The broad application of p27 in the clinical evaluation of breast cancer prognosis will require a consensus on methods of tumor fixation, staining, and scoring. This review will focus on mechanisms of p27 regulation in normal cells and how deregulation of p27 may arise in breast and other human cancers. The prognostic significance of p27 in human breast cancer and the possible therapeutic implications of these findings will also be reviewed.

Citing Articles

p27 Cell Cycle Inhibitor and Survival in Luminal-Type Breast Cancer: Gene Ontology, Machine Learning, and Drug Screening Analysis.

Park I, Noh Y, Min K, Kim D, Lee J, Son B J Breast Cancer. 2024; 27(5):305-322.

PMID: 39344410 PMC: 11543279. DOI: 10.4048/jbc.2024.0107.

Energy‑stress‑mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple‑negative breast cancer.

Lim J, Kim E, Song J, Ahn S Oncol Rep. 2024; 52(2).

PMID: 38904203 PMC: 11223027. DOI: 10.3892/or.2024.8760.

Therapeutic effects of hAMSCs secretome on proliferation of MDA-MB-231 breast cancer cells by the cell cycle arrest in G1/S phase.

Rahimi Lifshagerd M, Safari F Clin Transl Oncol. 2023; 25(6):1702-1709.

PMID: 36617361 DOI: 10.1007/s12094-022-03067-4.

A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.

Fong L, Lee J, Lin H, Ueno N, Zhang S Sci Rep. 2022; 12(1):2478.

PMID: 35169199 PMC: 8847659. DOI: 10.1038/s41598-022-06451-w.

Oncogenic and Tumor Suppressive Components of the Cell Cycle in Breast Cancer Progression and Prognosis.

Kashyap D, Garg V, Sandberg E, Goel N, Bishayee A Pharmaceutics. 2021; 13(4).

PMID: 33920506 PMC: 8072616. DOI: 10.3390/pharmaceutics13040569.

References

Becker K, Atkinson M, Reich U, Becker I, Nekarda H, Siewert J . E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994; 54(14):3845-52. View

Hengst L, Reed S . Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996; 271(5257):1861-4. DOI: 10.1126/science.271.5257.1861. View

Vlach J, Hennecke S, Amati B . Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 1997; 16(17):5334-44. PMC: 1170165. DOI: 10.1093/emboj/16.17.5334. View

Aktas H, Cai H, Cooper G . Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol. 1997; 17(7):3850-7. PMC: 232237. DOI: 10.1128/MCB.17.7.3850. View

Klijn J, Berns P, Schmitz P, Foekens J . The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev. 1992; 13(1):3-17. DOI: 10.1210/edrv-13-1-3. View

Zhu X, Ohtsubo M, Bohmer R, Roberts J, Assoian R . Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol. 1996; 133(2):391-403. PMC: 2120799. DOI: 10.1083/jcb.133.2.391. View

Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J . Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A. 2001; 98(9):5043-8. PMC: 33160. DOI: 10.1073/pnas.081474898. View

Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, HORII I . Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996; 85(5):707-20. DOI: 10.1016/s0092-8674(00)81237-4. View

Muss H, Thor A, Berry D, Kute T, Liu E, Koerner F . c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994; 330(18):1260-6. DOI: 10.1056/NEJM199405053301802. View

10.

Polyak K, Kato J, Solomon M, Sherr C, Massague J, Roberts J . p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994; 8(1):9-22. DOI: 10.1101/gad.8.1.9. View

11.

Ponce-Castaneda M, Lee M, Latres E, Polyak K, Lacombe L, Montgomery K . p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995; 55(6):1211-4. View

12.

Koff A, Ohtsuki M, Polyak K, Roberts J, Massague J . Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science. 1993; 260(5107):536-9. DOI: 10.1126/science.8475385. View

13.

Esposito V, Baldi A, De Luca A, Groger A, Loda M, GIORDANO G . Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997; 57(16):3381-5. View

14.

Slingerland J, Pagano M . Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000; 183(1):10-7. DOI: 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I. View

15.

Loden M, Nielsen N, Roos G, Emdin S, Landberg G . Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene. 1999; 18(16):2557-66. DOI: 10.1038/sj.onc.1202488. View

16.

Marygold S, Leevers S . Growth signaling: TSC takes its place. Curr Biol. 2002; 12(22):R785-7. DOI: 10.1016/s0960-9822(02)01294-0. View

17.

Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz M . Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 2001; 91(9):1745-51. DOI: 10.1002/1097-0142(20010501)91:9<1745::aid-cncr1193>3.0.co;2-h. View

18.

Cariou S, Donovan J, Flanagan W, Milic A, Bhattacharya N, Slingerland J . Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A. 2000; 97(16):9042-6. PMC: 16818. DOI: 10.1073/pnas.160016897. View

19.

St Croix B, Florenes V, Rak J, Flanagan M, Bhattacharya N, Slingerland J . Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996; 2(11):1204-10. DOI: 10.1038/nm1196-1204. View

20.

Chappuis P, Kapusta L, Begin L, Wong N, Brunet J, Narod S . Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000; 18(24):4045-52. DOI: 10.1200/JCO.2000.18.24.4045. View